albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
=== Injections and implants === In 1933 or 1934, Schering introduced progesterone in oil solution as a medication by intramuscular injection under the brand name Proluton. This was the first pharmaceutical formulation of progesterone to be marketed for medical use. It was initially a corpus luteum extract, becoming pure synthesized progesterone only subsequently. A clinical study of the formulation was published in 1933. Multiple formulations of progesterone in oil solution for intramuscular injection, under the brand names Proluton, Progestin, and Gestone, were available by 1936. A parenteral route was used because oral progesterone had very low activity and was thought to be inactive. Progesterone was initially very expensive due to the large doses required. However, with the start of steroid manufacturing from diosgenin in the 1940s, costs greatly decreased. Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were the first long-acting progestogen formulation. Pellets were reported to be extruded out of the skin within a few weeks at high rates, even when implanted beneath the deep fascia, and also produced frequent inflammatory reactions at the site of implantation. In addition, they were absorbed too slowly and achieved unsatisfactorily low progesterone levels. Consequently, they were soon abandoned, in favor of other preparations such as aqueous suspensions.
On 26 November 2018, the mayor of Moscow, Sergey Sobyanin, participated in the ceremony to launch the cable car above the Moskva River. This car connects the Luzhniki sports complex with Sparrow Hills and Kosygin Street. The trip from the viewpoint on Vorobyovy Gory to Luzhniki Stadium takes only five minutes, rather than 20 minutes by car.
== Bibliography == Hall, John (2011). Guyton and Hall Textbook of Medical Physiology (12th ed.). Philadelphia: Saunders/Elsevier. ISBN 978-1-4160-4574-8. Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; Loscalzo, Joseph (2011). Harrison's Principles of Internal Medicine (18th ed.). McGraw-Hill Professional. ISBN 978-0-07-174889-6. Susan Standring; Neil R. Borley; et al., eds. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Nicki R. Colledge; Brian R. Walker; Stuart H. Ralston, eds. (2010). Davidson's principles and practice of medicine (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. ISBN 978-0-7020-3085-7.
Sources: en.wikipedia.org
18 July – Starmer pledges £84m in funding for education, employment and humanitarian projects in Africa and the Middle East designed to stop illegal migration "at source". 19 July – Ukrainian president Volodymyr Zelenskyy visits Downing Street and addresses the cabinet, becoming the first foreign leader to address a British cabinet since 1997, and urges Keir Starmer to "show your leadership" by helping to remove restrictions on the use of weapons supplied to Ukraine. Sunak makes junior appointments to his shadow frontbench team, including some newly elected MPs, meaning 51 of the 121 Conservative MPs in parliament now have shadow ministerial posts. Foreign Secretary David Lammy confirms the UK will resume funding UNRWA, the UN's agency for Palestinian refugees. Shadow Secretary of State for Health and Social Care Victoria Atkins is criticised by House of Commons Deputy Speaker Christopher Chope for her behaviour during a parliamentary debate after she loudly interrupted Steve Reed, the Secretary of State for Environment, Food and Rural Affairs as he addressed the House. 20 July – Figures produced by the Institute for Fiscal Studies suggest the UK government would need to spend an extra £3bn to implement a 5.5% pay rise for teaching and NHS staff. July 2024 Welsh Labour leadership election: Welsh Labour officials agree a timeline for the election, with a new leader to be in place on 14 September. Nominations open for candidates entering the leadership contest.
Inherited immune deficiency – severe combined immunodeficiency, common variable immunodeficiency, ataxia–telangiectasia, Wiskott–Aldrich syndrome, immunodeficiency with short-limbed dwarfism, immunodeficiency with thymoma, purine nucleoside phosphorylase deficiency, genetic polymorphism Blood cell dysfunction – aplastic anemia Infectious diseases – viral (AIDS, SARS, West Nile encephalitis, hepatitis, herpes, measles, others), bacterial (TB, typhoid, pneumonia, rickettsiosis, ehrlichiosis, sepsis), parasitic (acute phase of malaria) Medications – chemotherapy (antilymphocyte globulin therapy, alemtuzumab, glucocorticoids) Radiation Major surgery Miscellaneous – ECMO, kidney or bone marrow transplant, hemodialysis, kidney failure, severe burns, celiac disease, severe acute pancreatitis, sarcoidosis, protein-losing enteropathy, strenuous exercise, carcinoma Immune dysfunction – arthritis, systemic lupus erythematosus, Sjögren syndrome, myasthenia gravis, systemic vasculitis, Behçet's-like syndrome, dermatomyositis, granulomatosis with polyangiitis Nutritional/Dietary – alcohol use disorder, zinc deficiency Like neutropenia, symptoms and treatment of lymphocytopenia are directed at the underlying cause of the change in cell counts.
From 2002 to 2004, Pinhasov carried out postdoctoral research at Johnson & Johnson Pharmaceutical Research and Development (Spring House, Pennsylvania, United States), where under the guidance of Dr. Douglas Brenneman he was engaged in the development of drugs for the treatment of neurodegenerative diseases. In 2005, Pinhasov joined the Department of Molecular Biology at Ariel University (formerly the College of Judea and Samaria) as an assistant professor. He was Head of the department from 2008 to 2014. In 2014, Pinhasov was appointed Vice-President and Dean of Research & Development at Ariel University, holding this position until 2020. In 2020 the Senate of Ariel University elected Professor Pinhasov as the Rector of Ariel University, succeeding Professor Michael Zinigrad, who held this office for 12 years. In September 2023, in recognition of his contribution to academic ties between Israel and Kazakhstan, the Senate of Astana Medical University (AMU) awarded Prof. Albert Pinhasov the title of honorary professor.
Sources: en.wikipedia.org
== Medical use == It is used to treat both type 1 and type 2 diabetes. A recent Cochrane systematic review also compared the effects of insulin detemir to NPH insulin and other insulin analogues (insulin glargine, insulin degludec) in both children and adults with Type 1 diabetes. With respect to blood sugar management, it appears to work better than NPH insulin, however this finding was inconsistent across included and previous studies. In the same systematic review no other clinically significant differences were found between different insulin analogues in either adults nor children.
On April 17, Ty Cobb, a former member of Trump's legal counsel during his first term in office, claimed that Trump displayed symptoms of dementia, characterizing the linguistic changes displayed in the Truth Social posts as "suggestive of the absence of any frontal lobe controls." Cobb additionally highlighted the late-night timestamps of the posts and Trump's apparent dozing off at Cabinet meetings as aligning with sleep cycle reversals seen in Alzheimer's disease, claiming that the combination of these behavioral traits characterized an acceleration in cognitive decline. White House spokesman David Ingle responded to both Crockett and Cobb's comments by praising Trump's "sharpness, unmatched energy, and historic accessibility" while accusing Crockett of aiding in an alleged cover-up of Joe Biden's mental decline as president and characterizing Cobb as "[a] severe case of Trump Derangement Syndrome." NATO official Paul Fritch also contested the mental illness characterization, speculating that Trump's behavior was instead the result of frustration towards his inability to bring the Iran war to a quick resolution. On June 2, journalist Aaron Rupar tweeted that Trump had made no public appearances since May 27 when he had attended a Cabinet meeting with a pre-recorded interview being released during that time, in response many commentors questioned the apparent pattern of Trump disappearing from public commitments for about a week each month.
Most of the rest of the world excluded prisoners as potential research subjects following formulation of the Nuremberg Code, based on its assertion that acceptable experimental subjects must be "so situated as to be able to exercise free power of choice". Despite regulations that limit circumstances where inclusion of vulnerable populations in clinical trials is permitted, such groups, such the economically disadvantaged, continue to be made part of research through coercive means as recently as 2015. International clinical trials day is celebrated on 20 May. The acronyms used in the titling of clinical trials are often contrived, and have been the subject of derision.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.